Myneedu Vithal Prasad, Singhal Ritu, Khayyam Khalid Umer, Sharma Prem Prakash, Bhalla Manpreet, Behera Digamber, Sarin Rohit
National Reference Laboratory & WHO Center of Excellence (Tuberculosis), Department of Microbiology, National Institute of Tuberculosis and Respiratory Diseases, New Delhi 110030, India.
Department of Epidemiology, National Institute of Tuberculosis and Respiratory Diseases, New Delhi 110030, India.
J Epidemiol Glob Health. 2015 Dec;5(4):365-73. doi: 10.1016/j.jegh.2015.04.002. Epub 2015 May 2.
There is limited information of level of drug resistance to first-line and second line anti-tuberculosis agents in treatment naïve pulmonary tuberculosis (PTB) patients from the Indian region. Therefore, the present prospective study was conducted to determine the antimicrobial susceptibility to first-line and second line anti-TB drug resistance in such patients. Sputum samples from consecutive treatment naïve PTB cases registered in Lala Ram Sarup (LRS) district, under RNTCP containing 12 Directly Observed Treatment Centre's (DOTS), were enrolled using cluster sampling technology. A total of 453 samples were received from July 2011 to June 2012. All samples were cultured on solid medium followed by drug susceptibility to first and second line anti-tubercular drugs as per RNTCP guidelines. Primary multi-drug resistance (MDR) was found to be 18/453; (4.0%). Extensively drug resistance (XDR) was found in one strain (0.2%), which was found to be resistant to other antibiotics. Data of drug resistant tuberculosis among treatment naïve TB patients are lacking in India. The presence of XDR-TB and high MDR-TB in small population studied, calls for conducting systematic multi-centric surveillance across the country.
关于印度地区初治肺结核（PTB）患者对一线和二线抗结核药物的耐药水平，目前可用信息有限。因此，开展了本前瞻性研究，以确定此类患者对一线和二线抗结核药物的抗菌药敏情况。采用整群抽样技术，纳入在拉腊·拉姆·萨鲁普（LRS）区登记的、来自12个直接观察治疗中心（DOTS）的连续初治PTB病例的痰液样本。2011年7月至2012年6月共收到453份样本。所有样本均在固体培养基上培养，然后按照国家结核病控制规划（RNTCP）指南，对一线和二线抗结核药物进行药敏检测。发现原发性耐多药（MDR）为18/453；（4.0%）。在一株菌株中发现广泛耐药（XDR）（0.2%），该菌株对其他抗生素也耐药。印度缺乏初治结核病患者中耐药结核病的数据。在研究的小群体中存在广泛耐药结核病和高耐多药结核病，这就需要在全国范围内开展系统的多中心监测。
